Regeneron and Sanofi will cut the price of their cholesterol drug Praluent by 60 percent to $5,850 a year, matching an unprecedented move that rival Amgen made with its medicine Repatha, the drug makers said Monday.

The two cholesterol drugs are now becoming an experiment in drug pricing. Praluent and Repatha were once expected to generate more than $1 billion in annual sales each. In 2015, executives at CVS Health, the pharmacy benefit manager, warned that together the medicines, which are given as injections, could cost the U.S. health care system $150 billion.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy